Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Enzalutamide capsules	TA377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide capsules	TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer	For hospital use only
Epirubilin solution for injection	TA250 - Eribulin for the treatment of locally advanced or metastatic breast cancer TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Epoetin beta syringe (Neorecormon)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG Commissioned for use in cancer - NICE TA323.
Eptifibatide injection	TA47 - Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes	Hospital use only
Erlotinib tablets	TA162 - Erlotinib for the treatment of non-small-cell lung cancer TA374 - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy TA258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer TA295 - Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy
Ertugliflozin (Steglatro®)	TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept	TA103 - Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept syringe	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Etelcalcetide	TA448 - Etelcalcetide for treating secondary hyperparathyroidism

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.